Plain-English translation of NCT06204835 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new surgical approach for people with liver cancer who are having surgery to remove the cancer. Before your operation, you'll receive an injection of a fluorescent dye called RDCy7 that highlights cancer cells. During surgery, doctors will use special imaging to see where the dye lights up, helping them identify and remove cancer more precisely.
During liver cancer surgery, it can be difficult for surgeons to see all the cancer, especially smaller spots that are easy to miss. This new fluorescent dye is designed to make cancer cells glow during surgery, so doctors can be more confident they've removed all the cancer and leave healthy liver tissue behind.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the fluorescent dye (RDCy7) before your scheduled liver surgery. During the operation, your surgical team will use special imaging equipment to visualize where the dye highlights cancer cells, which will help guide the removal of cancerous tissue. The study involves your surgery itself and related monitoring to evaluate how well this imaging technique works.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China